Study Reveals Immune Checkpoint Inhibitor Treatment and Monitoring Practices Post-Remission
Source: Dermatology Times, January 2025
Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.
Following complete melanoma remission, immune checkpoint inhibitor (ICI) treatment typically continues for the next 3 to 36 months, with 66% of German Dermatologic Cooperative Oncology Group centers continuing treatment for 6 months, according to a study published in the Journal der Deutschen Dermatologischen Gesellschaft.
Within the first full year after discontinuing treatment with ICIs, researchers found that most centers conducted staging intervals via imaging every 3 months, with greater than 60% of centers continuing imaging annually as far out as 4 to 5 years post treatment discontinuation.